Investors in Actinium Pharmaceuticals Urged to Consider Legal Action for Securities Fraud

Investors Invited to Join a Class Action Lawsuit Against Actinium Pharmaceuticals

If you purchased securities of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) during the specified period of October 31, 2022, to August 2, 2024, there’s a crucial opportunity that might be of interest to you. The Rosen Law Firm, a prominent global legal practice specializing in the rights of investors, is urging eligible parties to come forward as potential lead plaintiffs in an ongoing class action lawsuit concerning alleged securities fraud.

What You Need to Know

The key date for potential lead plaintiffs is approaching: May 26, 2025. If you made purchases of Actinium securities during the class period, you may qualify to claim damages without incurring any out-of-pocket expenses, thanks to a contingency fee structure. This means that legal fees would be contingent upon a successful recovery in the case.

To join the class action, investors can visit the Rosen Law Firm's dedicated page or directly contact Phillip Kim, Esq., either by phone or email, to learn more about the requirements and the legal process involved. Once a class action is initiated, being a lead plaintiff allows individuals to represent the broader group of affected investors during legal proceedings.

Understanding the Allegations

The heart of this lawsuit revolves around claims that inaccurate and misleading information was disseminated by the defendants regarding Actinium's clinical trial data, specifically related to their Iomab-B Biologics License Application (BLA). The allegations assert that:
1. Data from the Sierra Trial would likely not meet the FDA's standards for approval.
2. Additional analyses presented to mitigate the poor trial outcomes could also fail to satisfy regulatory guidelines.
3. This negligence could lead to the FDA either rejecting the Iomab-B BLA or delaying its review, damaging investors who had confidence in the company's statements regarding its future.

As the truth behind these claims emerges, stakeholders have experienced financial losses, prompting the need for legal recourse.

Why Choose Rosen Law Firm?

Choosing the right representation is crucial in securities litigations like this one. The Rosen Law Firm has established a solid reputation in navigating complex securities class actions, consistently achieving successful settlements on behalf of investors. They have recovered significant sums in the past, and their recognition as a leading firm in this area is well-established.

Since 2013, the firm has consistently been ranked among the top providers of class action settlements, including a notable record in securing over $438 million for investors in a single year. The statistics speak volumes about their experience and dedication to serving the interests of investors.

Next Steps for Investors

If you believe you qualify, it’s paramount to act promptly. You have options: you may choose to take an active role in the lawsuit as a lead plaintiff, or remain an absent class member without immediate action. The choice of legal counsel can significantly impact the outcomes, so investors are advised to select a firm with the necessary credentials for such matters.

Investors can stay informed by following updates from the Rosen Law Firm on their social media channels, including LinkedIn and Twitter, to receive ongoing information about the case and other relevant legal insights.

This is an important juncture for those affected by the situation surrounding Actinium Pharmaceuticals. Delaying action could mean losing the chance for fair compensation under the law.

For more information and to take action, potential claimants should navigate to the Rosen Law Firm's website as soon as possible. Your financial recovery could depend on it.